Trial record 9 of 27 for:
" July 30, 2008":" August 29, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
This study has been completed.
Information provided by (Responsible Party):
David Haas, Vanderbilt University
First received: August 4, 2008
Last updated: March 2, 2015
Last verified: March 2015
This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how much RGV gets into the CSF.
||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
||Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||February 2011 (Final data collection date for primary outcome measure)
Experimental: Open label oral raltegravir
Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
400mg orally every 12 hours for 7 days
Other Name: MK-0518
The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in the blood-brain barrier where it limits entry of substrate drugs into the central nervous system. Raltegravir (MK-0158), a new HIV-1 integrase inhibitor and potentially major addition to the therapeutic armamentarium against HIV, is a substrate for P-gp. Studies are warranted to elucidate the relevance of P-gp transport for raltegravir in the central nervous system.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Able to give informed consent.
- Negative HIV-1 serology.
- At least 18 but no more than 55 years of age.
- Body mass index <30.
- Estimated creatinine clearance ≥ 50 mL/minute within 30 days prior to study entry.
Within 30 days prior to study entry:
- Absolute neutrophil count ≥ 1,000/mm3.
- Hemoglobin ≥ 12.5 g/dL for males and ≥ 11.5 g/dL for females.
- Platelet count ≥ 100,000/mm3.
- AST, ALT, and total bilirubin within normal range.
- Alkaline phosphatase < or = 1.5 x upper limit of normal.
- Female study volunteers of reproductive potential must have a negative serum or urine pregnancy test performed within 30 days before study entry.
- Must agree not to participate in a conception process.
- Drug transporter gene ABCB1 position 3435 genotype C/C or T/T.
- Use of any medication that is metabolized by CYP3A or UGT1A1.
- Anticipated need to take any medication that is metabolized by CYP3A or UGT1A1 during the study.
- Active drug use or dependence.
- Inability to abstain from alcohol-containing beverages, grapefruit, and grapefruit juice.
- Serious illness that would interfere with study participation.
- Hospitalization for any reason or therapy for serious illness within 14 days prior to study entry.
- History of hypersensitivity to study drug or its formulation.
- As determined by the investigator, a significant active or previous history of cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s). This is inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal conditions that may affect drug absorption, etc.
- Evidence of CNS infection or space occupying lesion by history or physical examination.
- History of significant CNS disorder.
- Prisoners or subjects who are compulsorily detained.
- ABCB1 position 3435 C/T heterozygosity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00729924
|Vanderbilt Therapeutics Clinical Research Site
|Nashville, Tennessee, United States, 37204 |
||David W Haas, MD
||David Haas, Professor of Medicine, Vanderbilt University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 4, 2008
|Results First Received:
||May 27, 2014
||March 2, 2015
||United States: Food and Drug Administration
United States: Institutional Review Board
Keywords provided by Vanderbilt University:
ClinicalTrials.gov processed this record on March 26, 2015